EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus

Ji Hyung Lim, Dowoon Han, Gianfranco C Velasco, Young Jun Seo, Jae Sang Han iD, Jung Mee Park, Jae Hyun Seo iD, So Young Park iD, Shi Nae Park iD

The Laryngoscope · 2026

DOI: 10.1002/lary.32447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Ji Hyung Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Tinnitus, Ear, Middle, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Investigating the efficacy and safety of intratympanic Botulinum toxin (IT‐BTX) injection as a novel treatment for middle ear myoclonic tinnitus (MEMT).

Methods

Medical records and tinnitus questionnaires of the patients with MEMT who underwent IT‐BTX were retrospectively reviewed. The efficacy of IT‐BTX on MEMT as well as its safety were evaluated by audiology tests and tinnitus questionnaires.

Results

A total of 57 patients who completed the questionnaires at pre‐ and post‐IT‐BTX were enrolled. Tinnitus handicap inventory (THI) scores decreased significantly from pre‐IT‐BTX (44.31 ± 26.8) to 31.42 ± 23.6 ( p < 0.001), 32.92 ± 24.9 ( p = 0.004), and 25.71 ± 22.9 ( p < 0.001) at 1‐, 3‐, and 6‐months post‐IT‐BTX, respectively. Additionally, visual analog scales (VAS) of loudness (LD), awareness (AW), annoyance (AN), and effect on life (EF) significantly decreased post‐IT‐BTX ( p < 0.05): LD from 4.19 ± 2.4 to 2.47 ± 2.0, 2.89 ± 2.2, and 2.38 ± 1.9 at 1‐, 3‐, and 6‐months; AW from 41.75 ± 29.5 to 24.38 ± 23.3, 26.94 ± 23.3, and 22.10 ± 21.7; AN from 5.00 ± 2.8 to 2.82 ± 2.1, 3.47 ± 2.4, and 2.78 ± 2.2; EF from 4.82 ± 2.8 to 2.89 ± 2.2, 3.28 ± 2.4, and 2.73 ± 2.2 at 1‐, 3‐, and 6‐months post‐IT‐BTX. Notably, 40.3% of the IT‐BTX patients experienced a complete cure of their MEMT symptoms, while 50.8% demonstrated partial resolution after IT‐BTX. There were no side effects or complications after IT‐BTX during their follow‐up period. Comparing delta values between the single injection group and multiple injection group revealed significant differences in VAS LD at the post‐1‐month time point and between the 1‐month and 6‐month intervals.

Conclusion

IT‐BTX is an effective, safe treatment for MEMT, significantly improving symptoms without complications, and offers a promising alternative before middle ear tendon resection. Level of Evidence: 4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TinnitusEar, MiddleBotulinum Toxins, Type ANeuromuscular AgentsMyoclonusHumansMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeAdultInjection, IntratympanicSurveys and QuestionnairesAged

Stichwörter der Autor:innen

botulinum toxinintratympanic injectionmiddle ear myoclonic tinnitus

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Otolaryngology-Head and Neck Surgery, Rizal Medical Center, Pasig City, Philippines.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Gangneung Asan Hospital, College of Medicine University of Ulsan, Gangneung, Korea.
  • Department of Otolaryngology-Head and Neck Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Jae Sang Han, Jae Hyun Seo, So Young Park, Shi Nae Park

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Lim, J. H., Han, D., Velasco, G. C., Seo, Y. J., Han, J. S., Park, J. M., Seo, J. H., Park, S. Y., & Park, S. N. (2026). Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus. The Laryngoscope. https://doi.org/10.1002/lary.32447

Vancouver

Lim JH, Han D, Velasco GC, Seo YJ, Han JS, Park JM, et al. Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus. The Laryngoscope. 2026. doi:10.1002/lary.32447

BibTeX
@article{Lim2026,
  author = {Lim, Ji Hyung and Han, Dowoon and Velasco, Gianfranco C and Seo, Young Jun and Han, Jae Sang and Park, Jung Mee and Seo, Jae Hyun and Park, So Young and Park, Shi Nae},
  title = {Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.32447}
}
Kostenlos starten →